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Abstract: The question of whether anesthetic, analgesic or other perioperative intervention during
cancer resection surgery might influence long-term oncologic outcomes has generated much attention
over the past 13 years. A wealth of experimental and observational clinical data have been published,
but the results of prospective, randomized clinical trials are awaited. The European Union supports
a pan-European network of researchers, clinicians and industry partners engaged in this question
(COST Action 15204: Euro-Periscope). In this narrative review, members of the Euro-Periscope
network briefly summarize the current state of evidence pertaining to the potential effects of the most
commonly deployed anesthetic and analgesic techniques and other non-surgical interventions during
cancer resection surgery on tumor recurrence or metastasis.
Keywords: cancer; anesthesia; analgesia
1. Introduction
Surgery (under anesthesia) is an important part of modern health care, helping millions of
people lead healthier, more productive lives [1]. More than 310 million major surgical procedures are
performed worldwide every year [2]. While the value of surgery is clear, little is known about the
impact of anesthesia or other perioperative factors on subsequent health status and quality of life,
which can sometimes be compromised. For example, surgical tumor excision is the primary approach
to breast, colon, brain, prostate, and several other cancers [3].
Preclinical and clinical studies support the hypothesis that anesthesia influences cancer biology
and outcomes. Although there is plenty of retrospective published data and some prospective
randomized studies available and ongoing, these are not sufficiently conclusive to suggest changes
in clinical practice. The strongest support for a role of anesthetics on cancer biology comes from
preclinical studies. However, the literature is sparse, often conflicting, and preclinical studies cannot
fully reproduce the complexity of human physiology during the perioperative period.
A previous consensus statement was published in 2014 but has not been updated [4]. In 2016, the
EU supported a COST Action (Euro-Periscope, 15204), a network of researchers, industry partners, and
clinicians interested in this question, to form a pan-European collaboration. In the current narrative
review, members of Euro-Periscope briefly summarize the current state of evidence pertaining to
the potential effects of the most commonly deployed anesthetic and analgesic techniques and other
perioperative non-surgical interventions during cancer resection surgery on tumor recurrence or
metastasis. After two-rounds of consultation with all of the members, aiming to provide a more
complete vision, updates were proposed and consensually accepted by the entire panel. The highest
level of evidence available illustrates each topic.
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2. Update on Methodology
Anesthesia and Cancer Research: Need for Translational Prospective Studies and Methodological Adaptations
Globally, research into the impact of anesthesia on cancer during the last twenty years has focused
either at the pre-clinical or clinical level. This disconnected approach has led to inconsistent selection
of endpoints and a limited perspective in a poorly understood field. A similar problem has been
highlighted in perioperative pain research [5]. Recently, a more consistent approach towards defining
oncological endpoints was published [6,7].
Inevitably, in some cases, the quality of biological studies could be improved by ensuring an
adequate number of experiments to provide more robust statistical analysis. Likewise, for translational
studies ideally testing a single primary hypothesis, the sample size should be calculated according to
the true variance of the data and the minimum biological effect.
Transcriptomic and genomic studies testing multiple biological hypotheses cannot be interpreted
only from p-values. Therefore, it is recommended that sample size should be calculated and data
analysis performed according to the tolerable False Discovery Rate (FDR = proportion of false positives
among the declared significant results) and False Negative Rate (FNR, or sensitivity) [8]. As FDR
depends on sample size, it is proposed by some authors to include a minimum of 50 subjects per
group [8].
Ideally, translational projects should combine omics approaches in conjunction with
epidemiological confirmation of the disease as well as clinical trials, when appropriate. Preferably, this
should be done in combination with analyses of clinically relevant endpoints and biologically promising
biomarkers. This may permit identification of specific mechanisms that could be addressed, such as
perioperative angiogenesis and neuroimmune interactions. Last but not least, these interventions may
take place in multi-arm/platform trials, particularly in complex perioperative settings.
3. Update on Biology
3.1. Perioperative Angiogenesis in Breast Cancer
Catecholamines, prostaglandins, and angiogenic factors are secreted abundantly during the
perioperative period in response to stress and surgery and were shown by translational studies as
possible promoters of tumor metastasis. Circulating tumor cells are seen in all cancers and transient
systemic inflammation accompanying surgery can enhance capillary leakage facilitating angiogenesis
of dormant micrometastasis, the proliferation of dormant cells and seeding of circulating cancer stem
cells resulting in early relapse.
Epidemiologic studies suggest that the choice of anesthetics may affect recurrence in breast cancer
through changes in angiogenesis. Studies in a xenograft model showed that antiangiogenic therapy in
the perioperative or direct postoperative period following primary breast tumor resection reduces
progression of bone metastasis [9].
Perioperative administration of the NSAID ketorolac (non-steroidal anti-inflammatory drug) has
been associated with a significant reduction in early recurrence following breast cancer surgery [10].
NSAID may interfere with the SDF1-CXCR4 axis in the cyclo-oxygenase type 2-prostaglandins pathway
(COX2-PGE-SDF1).
Comparing general anesthesia with sevoflurane-opioids versus propofol-paravertebral block
showed that the latter inhibits cancer cell proliferation, reduces the stress response, as well as
metalloproteinases and transforming growth factor β [11]. Opioids may be proangiogenic through an
immunosuppressive effect and can also transactivate VEGF receptor by Src activation [12]. Similarly,
sevoflurane may promote angiogenesis by increasing VEGF-C serum concentrations, whereas propofol
can have an anti-angiogenic effect [12].
However, using analgesic doses of morphine and other opioids in preclinical studies in mouse
models for HER2+ breast cancer found no adverse effect on tumor metastatic dissemination,
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angiogenesis and the concentration of tumor-infiltrating immune cells after surgery, suggesting
that opioid analgesics can be used safely [13].
In summary, there are no conclusive studies relating to angiogenesis in breast cancer patients that
should change our clinical practice.
3.2. Anesthetic Neuromodulation and Cancer Biology
The nervous system is a primary actor in early and late cancer development. Many cancers e.g.,
colon and prostate present a specific growth pattern called “perineural invasion” which is driven
by neurons. The growth of some cancers like prostate, pancreas, and breast cancer, is associated
with “neurogenesis” and an abundant infiltration of the tumor by the autonomic nervous system.
The stress response, results from stimulation of the sympathetic system, which enhances tumor
growth through immunosuppression and beta-adrenergic receptor stimulation, expressed on tumor
cells [14]. In animal studies, sympathectomy slows cancer progression, and human retrospective data
suggest that cancer patients taking beta-blockers have lower recurrence rates and lower mortality [15].
The parasympathetic system modulates cancer progression through cholinergic receptors and the
vagus nerve. Stimulation of the vagus nerve slows tumor progression by reducing sympathetic
activity and oxidative stress, and by modulating the innate and adaptive immune responses [16].
Finally, sensory neurons and the tumor micro-environment are strongly involved in the modulation of
inflammation, in local tissue homeostasis, in healing and development, especially under conditions
of psychological stress. The activation of sensory neurons during pain enhances tumor progression
and metastatic potential. Regional anesthesia blocks somatic nociception and inhibits sympathetic
preganglionic outflow (functional sympathectomy) during surgery. Moreover regional anesthesia, by
blocking sympathetic nervous system output, induces a prevalence of parasympathetic tone. Local
anesthetics can also modulate autonomic receptors [17]. For these reasons, more studies are needed to
investigate the action of regional anesthetic neuromodulation on cancer progression.
3.3. Surgery and Immunomodulation
Surgery evokes an acute-phase response, described above as the stress response that includes a
transient immunosuppression and alterations in gastrointestinal function and there is clear evidence
that sarcopenia, malnutrition, arginine bioavailability, and a high arginase activity state contributes to
adverse surgical outcomes. Approaches to improve this will be discussed later. In short, approaches
include pharmaconutrition, aimed at improving immune function (termed immunonutrition) and both
parenteral and enteral approaches including amino acids (arginine and glutamine), lipids (omega-3 fatty
acids), micronutrients (vitamins C and E), and nucleotides [18]. The benefits of perioperative treatment
with immunonutrients are well documented and include reduction of postoperative complications,
reduced loss of skeletal mass, modulated inflammatory response, and improved protein synthesis
after surgery [19–32]. It is known that taurine supplementation augments immune function and
protects the gut from intestinal barrier dysfunction induced by surgery [33]. The same phenomenon of
complex immune dysfunction is seen in cancer patients and clinical data show a correlation between
high-density leukocytic infiltration in solid tumors and poor patient outcomes. Inflammatory cells
produce pro-angiogenic mediators and extracellular proteases that influence metastases by inducing
tissue remodeling, and tumor angiogenesis [34]. Resolvin D1, a metabolite of Omega-3 fatty acids
through the Cox-2 pathway has been shown to enhance endogenous clearance of tumor cell debris
following chemotherapy thus complementing cytotoxic cancer therapies. Perioperative treatment
with Resolvin D1 in a murine model reduces lung metastases upon surgical excision of primary
breast tumors in a murine model [35]. However, the role for immunomodulating formulas within the
enhanced recovery pathway for cancer patients undergoing surgery remains unclear.
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3.4. Animal Studies of Perioperative Drugs in the Setting of Cancer
As the scientific investigation of the potential effects of perioperative agents on cancer evolves
from retrospective analysis of human trials to potential prospective work, animal investigations can
play an important role in refining potential therapeutic strategies for such studies. Animal models of
tumors have numerous advantages and drawbacks when compared with human research. Animal
models frequently have better control of variables and deliver faster results than human studies.
There is, however, no perfect non-human cancer model; they may lack many of the biological steps of
tumor development and metastasis as well as not necessarily reflecting the complex immune system
and tumor interplay seen in human disease. Although there have been limited animal studies to date,
lidocaine infusion has been implicated in having a beneficial role in the perioperative setting and as a
chemotherapeutic agent in the non-operative setting [36]. Propofol has been shown to be protective
or non-inferior to controls using in vivo models [36]. Some perioperative agents have shown signals
that may be potentially harmful, or promote metastasis, in the setting of cancer. Such agents include
corticosteroids and dexmedetomidine, which have been shown to increase metastasis when studied in
laboratory experiments in the setting of malignancy [37] but not in other in vivo experiments and large
retrospective series [38–41]. Results of the translational work should then be interpreted with caution
due to the small numbers of studies and the intrinsic weaknesses associated with in vivo models.
However, they are useful in hypothesis development and potential strategies for improving outcomes
in human disease.
4. Update on the Available Evidence Regarding Anesthetic/Analgesic Technique
4.1. Metastasis: A Role for Amide-Type Local Anesthetics?
Metastases account for the great majority of cancer-associated deaths, yet this complex process
remains the least understood aspect of cancer biology. The dissemination of cancer cells from primary
tumors and subsequent seeding of new tumor colonies in distant tissues involves a multistep process
known as the invasion-metastasis cascade, in which the Src system seems to play an important
role [42]. Lidocaine at clinically achievable concentrations has been shown in vitro to statistically
inhibit the phosphorylation of Src and the ICAM-1 expression in human lung cancer cells [43]. This
study also demonstrated that the effect was independent of the function of the sodium ion channel.
Moreover, lidocaine has also been shown to inhibit NaV1.5 sodium ion channels [44], and the TRPV6
receptors [45], inhibit the activity of epidermal growth factor in humans with tongue cancer [46], induce
apoptosis and suppress tumor growth in human hepatocellular cells in vitro [36], and cause time- and
dose-dependent demethylation of deoxyribonucleic acid in breast cancer cell lines in vitro [47]. Recently,
lidocaine in vitro was shown to inhibit cytoskeletal remodeling and human breast cancer migration [48].
Lidocaine can also have beneficial effects on the immune system. Yardeni et al. demonstrated that a
continuous infusion of lidocaine reduced plasma concentration of cytokines including IL-6, IL-8, and
IL-1Ra, and improved the function of lymphocytes in response to phytohemagglutinin in patients
undergoing transabdominal hysterectomy [49]. However, it is important to point out that there are no
preclinical studies to show that clinically available doses can improve the oncologic outcome. Ongoing
studies dealing with IV infusion of lidocaine are promising and may improve the outcome of patients
undergoing cancer surgery. But some anesthetic agents may also be potentially deleterious.
4.2. Volatile or Inhaled Anesthesia and Cancer Cell Biology
Among several perioperative factors, some anesthetic agents may promote tumorigenesis and
metastatic recurrence. Indeed, it has been shown that isoflurane can increase hypoxia inducible factor
(HIF) [50], promoting angiogenesis through vascular endothelial growth factor (VEGF) signaling, likely
accelerating cancer progression [51]. Molecular entities that are responsible for angiogenesis, migration,
invasion, proliferation and even chemoresistance have been shown to be significantly enhanced by
isoflurane through potentiation of the tumorigenic PI3K/Akt/mTOR cell signaling pathway and then in
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turn up-regulation of HIFs, with effects sustained for up to 24 h after a two-hour isoflurane exposure [51].
In contrast, propofol has been shown to antagonise these signaling pathways, as evidenced by a
reduction in cellular levels of phosphorylated-Akt and HIF-1 alpha expression. Interestingly, propofol
has also been shown to suppress the pro-malignant effects of isoflurane in vitro [51]. In line with these
findings of in vitro work, retrospective clinical studies [52–55] (see below Section 4.3) also showed that
TIVA is better than inhalational anesthetics during cancer surgery regarding long-term survival.
4.3. Retrospective and On-Going Randomized Clinical Trials on TIVA versus Inhalation
Retrospective clinical studies evaluated postoperative outcome after total intravenous anesthesia
(TIVA) versus inhalation anesthesia in cancer patients. In their study including approximately 5,200
patients undergoing surgery for different types of cancer, Wigmore et al. found that inhalational
(volatile) anesthesia was associated with a hazard ratio of 1.46 after multivariate analysis when
compared with TIVA [52]. Recently, Zheng et al. found the same results, an association between
better survival and TIVA in patients with gastric cancer undergoing surgery [53]. Lee et al. reported
a better 5 years outcome after TIVA for radical mastectomy [54] and Jun et al. a better outcome
in patients undergoing esophageal cancer surgery and TIVA [55]. A recent meta-analysis of these
four retrospective clinical studies suggested that TIVA might be the preferred anesthetic choice in
cancer surgery; however, the quality of evidences is low [56]. In contrast with these findings, a
recent retrospective study in patients with lung cancer found no benefit in outcome after TIVA when
compared with inhalation anesthesia [57]. To make the picture more complex, it should be pointed out
that some studies have shown differences in overall survival, with no change in relapse-free survival.
This may arise as a result of systemic opioid analgesics (i.e., opioid-related cardiovascular events,
nocturnal arrhythmia, disordered breathing and/or infections).
Several prospective clinical studies comparing the outcome after TIVA versus inhalation
anesthesia for cancer surgery are currently under development or in progress. The effects of regional
analgesia/anesthesia and of local anesthetics are also being assessed in some RCTs.
Most prospective RCTs compare TIVA ± regional anesthesia with inhalation anesthesia for breast
and colon cancer surgery (NCT2089178, NCT00938171, NCT418457, NCT2005770, NCT01975064).
Other types of cancer are also being studied e.g., pancreatic cancer (NCT2335151) [58]. There are a
few studies comparing the effects of TIVA versus inhalation anesthesia and of lidocaine infusion on
long-term outcomes and recurrence rates for breast and colon cancer (NCT02839668, NCT02786329,
NCT01204242).
Finally, we will consider the possible role of opioids, in negative outcomes for patients undergoing
cancer surgery.
4.4. Opioids and Cancer Recurrence
Most experimental research, consisting of both cancer cell culture studies and in vivo animal
models of cancer, suggest that opioids facilitate cancer cell proliferation (such as migration, invasion,
and angiogenesis) and therefore could be detrimental in cancer patients [59–61]. However, some
laboratory studies have shown the opposite effect i.e., opioids may have an inhibitory effect on cancer
cells and, depending on the animal model used, may not always enhance tumor growth. On balance
the evidence does not justify reduced perioperative opioid use, which could potentially lead to worse
outcomes due to the negative impact of pain [62].
There are several observational studies with conflicting results, the majority favoring an association
between opioid use during cancer surgery and increased risk of recurrence [63]. Also noteworthy is the
apparent association between use of the peripheral opioid antagonist methylnaltrexone, with longer
survival in cancer patients who receive opioids [64]. What is needed are prospective, randomized,
controlled clinical trials comparing opioid based analgesia perioperatively during tumor resection
surgery of curative intent with alternative anesthetic-analgesic techniques, with long-term oncologic
outcomes (recurrence free survival, overall survival) as the clinical endpoints, in combination with
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biological ones. Such studies take years to complete patient enrolment and follow-up, and one such
trial (NCT00418457) may report the results in 2019.
4.5. Opioid-Free Anesthesia and Cancer
Opioid-Free Anesthesia (OFA) based on the pre-, intra-, and postoperative administration of
analgesics known to prolong disease-free survival e.g., NSAIDs and LA might be a promising
therapeutic strategy for surgical cancer patients. OFA strategies for this group of patients may
include the use of propofol as a hypnotic, analgesia based on neuroaxial or locoregional techniques to
reduce/avoid the use of opioids, intravenous infusion of lidocaine from anesthesia induction to the
immediate postoperative period, use of beta-blockers and pre- and postoperative administration of
NSAID [65]. The effectiveness of other drugs such as dexmedetomidine or ketamine in improving
disease-free survival, if any, is more controversial. Further studies should be conducted in the future
to assess the role of these agents in treating tumor and metastatic disease [59]. However, assessing
the specific role of these drugs in preventing tumor relapse is challenging. First, it requires the
performance of multicenter trials involving patients with different types of cancer for which surgery is
the main therapeutic option [66]. Yet, to obtain significant results, a large sample of patients is required,
and long-term follow-up is necessary, as well a complex design seeing the multiple combinations of
pathological processes and therapeutic interventions. A first approach may be to compare paradigms
in analgesia, e.g., epidural analgesia versus the morphine use.
4.6. Morphine versus Epidural Analgesia in Colorectal Cancer Surgery, Lessons from an Ongoing Trial
The role of epidural analgesia (EDA) in improving long-term outcomes following colorectal cancer
surgery has been discussed [67]. One study from authors of this paper found that patients operated
for rectal but not colon cancer had a significantly longer survival time when regional anesthesia was
combined with general anesthesia as opposed to general anesthesia alone [68]. However, it was also
found in another study that epidural anesthesia as opposed to patient-controlled intravenous morphine
analgesia (PCA) does not reduce the perioperative inflammatory response to colorectal surgery [69].
The precise mechanism by which EDA might improve postoperative inflammation therefore remains
unclear. And the existence of a class effect regarding the influence of opioids on cancer, if any, should
not be automatically accepted, as this is not clear in the literature. In a prospective, randomized,
multicenter trial in patients undergoing surgery for colorectal cancer, 280 patients were randomized to
receive epidural anesthesia and analgesia for perioperative pain management or intravenous PCA
morphine. The primary aim of this study was to assess the time to cancer recurrence (by CT performed
yearly) or all-cause mortality. Interestingly, as surgical techniques evolve, there is stratification to
laparoscopic surgery/open-surgery and colon/rectal surgery. The study is expected to be complete by
the end 2019 and all patients will be followed-up for a period of 5 years.
Retrospective data on patients operated for rectal cancer surgery points to favorable outcome in
patients having epidural analgesia. No prospective study with an adequate number of patients has yet
been completed but important findings are awaited. Another promising adjunct to analgesia is the
NSAIDs, especially in the context of inflammation and COX-2 dependent mechanisms.
4.7. Inflammation and NSAIDs
The story of the NSAIDs in this context began with the identification of a bimodal pattern of hazard
of relapse among early stage breast cancer patients, in multiple databases. Using computer simulation
and access to a high-quality database from Milan for patients treated with mastectomy only, it was
proposed that relapses within 3 years of surgery are stimulated somehow by the surgical procedure.
Retrospective breast cancer data suggested a plausible mechanism. Use of ketorolac, a common NSAID
analgesic, was associated with superior disease-free survival [40,70]. The expected prominent early
relapse events in months 9 to 18 were reduced 5-fold. Transient systemic inflammation accompanying
surgery (identified by IL-6 in serum) could facilitate angiogenesis of dormant micrometastases and
Cancers 2019, 11, 592 8 of 15
proliferation of dormant single cells and could have been effectively blocked by the perioperative
NSAID. If this observation holds up to further scrutiny, it could mean that the use of this safe,
inexpensive and effective anti-inflammatory agent at surgery might substantially reduce early relapses
and reduce mortality by 25–50%.
The findings have recently been confirmed in a mouse-model by Krall et al. [71] and in a
retrospective study by Desmedt et al. [72].
However, the Ketorolac in Breast Cancer trial (NCT01806259), a multicenter, placebo-controlled,
randomized phase III trial in high-risk breast cancer patients, has recently shown that a single dose of
ketorolac tromethamine versus placebo 30 min before surgery, does not increase disease-free survival
in high risk breast cancer patients [73,74]. Overall survival is also comparable. As no safety concerns
were observed, multiple doses could be studied during the perioperative period. Considering these
inconsistent results, it can be suggested that this intervention should be studied further in future
randomized controlled clinical trials.
5. Other Perioperative Interventions
5.1. Perioperative Nutrition
Perioperative interventions that may have a positive effect on the outcome also include other
factors than anesthetic/analgesic techniques. Proper, patient-tailored nutrition plays a major role in
all kinds of cancer surgery. Its beneficial effect on short- and long-term outcomes is multifactorial.
Not only does it help the patient to recover faster from surgical trauma, but also decreases the number
and severity of postoperative complications [75]. Non-complicated postoperative outcomes enable
timely administration of oncological treatment as well as reduce the risk of applying suboptimal radio-
and chemotherapy doses, which happen in nutritionally compromised patients [76]. It has also been
shown that patients who suffer from postoperative complications have worse overall disease-free
survival [77].
Well-planned preoperative nutrition also helps to prepare a malnourished patient for surgery
and oncological treatment. Whenever possible, enteral or oral route is preferred as it helps to
maintain gastrointestinal physiology and mucosal integrity. For patients in whom enteral route is not
adequate, supplemental parenteral nutrition may be used. Patients without mechanical obstruction
of gastrointestinal tract should be prescribed oral nutritional supplements (ONS) as standard part of
their preoperative nutritional preparation. Standard ONS use has been shown to be effective in both
malnourished and non-malnourished, weight losing patients [78].
The Enhanced Recovery After Surgery (ERAS) paradigm has been proven safe and beneficial
in most surgical fields, including surgical oncology. The paradigm should be applied in all surgical
cancer patients, with early oral feeding where applicable and fluid restriction therapy [79,80].
Briefly, a modern, patient-tailored nutritional approach aimed at reducing nutritional deficiencies
and minimization of the fasting period should be a part of oncological treatment plan.
5.2. Perioperative Nutrition Protocol
The nutritional status of the patient significantly influences the outcome of the treatment, whether
it is obesity or malnutrition with loss of muscle mass [81]. Inadequate dietary support in the
perioperative period compromises the surgical outcome [82]. Up to 30 percent of patients hospitalized
for surgical oncology with major surgery need nutritional support according to NSR 2002 evaluation [83].
Bioimpedance measurements are adding quality and quantity data to nutritional status gained through
questionnaires and body mass index (BMI) data [84].
Some experiences show that it is possible to evaluate the patients multiple times by a nurse
dealing with nutrition in consultation with the anesthesiologist. For example, the first appointment
may be directly after the surgery counselling when the surgeon sets the date of surgery (usually two
weeks before the operation), on the day of surgery, upon leaving the intensive care unit (3rd day), on
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discharge from the hospital and the 15th and 30th postoperative day. The nurse can take bioimpedance
measurements in addition to patient history on nutritional habits and NSR 2002. Preliminary results
show that the data gained through NSR 2002, bioimpedance and primary laboratory results can be
effectively used to tailor individual nutrition plan either enteral or parenteral. Bioimpedance proved to
be a useful additional surveillance tool as it added objectiveness to muscle loss evaluation which is often
an underestimated marker of malnutrition, even if loss of muscle mass due to cancer cachexia would
not be easily differentiated [85]. This can be done conjointly to a preoperative physical rehabilitation,
called prehabilitation.
5.3. Prehabilitation
The individual’s level of physical fitness prior to an operation may be predictive of postoperative
outcome: physical fitness is an overall term encompassing aerobic capacity, endurance, muscular
strength, and body composition [86–90]. Prehabilitation i.e., improving the functional capacity of
an individual to withstand a stressful event, may improve postoperative outcome and decrease the
associated hospital costs of operative intervention while enhancing patient quality of life [91,92].
A recent review has shown that preoperative exercise therapy may improve physical fitness of patients
prior to a major abdominal operation although the ability to improve postoperative outcomes is unclear
due to the lack of randomized controlled trials [90].
A recent meta-analysis by Moran et al. has shown that prehabilitation, consisting of inspiratory
muscle training, aerobic exercise, and resistance training, appears to decrease the incidence of all
postoperative complications in patients undergoing intra-abdominal operations (Odds Ratio, OR: 0.59,
95% CI: 0.38–0.91) [93]. This effect was strongest when prehabilitation was compared with usual care
or breathing exercises only (OR: 0.35, 95% CI: 0.17–0.71). Furthermore, prehabilitation significantly
decreased the incidence of postoperative pulmonary complications (OR: 0.27, 95% CI: 0.13–0.57), which
were measured as the primary complication of interest in the majority of studies reviewed.
The main obstacle to the spreading of nutritional therapy as of prehabilitation is compliance.
Current standards in cancer care demand minimal delay between cancer diagnosis and treatment, thus
incorporating these interventions into a time-restricted clinical pathway may be challenging.
To overcome this limit, prehabilitation and ERAS, both aimed to minimize operative stress and
complications, can be integrated. However, the literature specific to ERAS and prehabilitation is limited,
and the two programs are seldom combined [94]. The designing of further RCTs should be considered
essential in this field. The important question remains, does prehabilitation improve outcomes?
5.4. Does Prehabilitation Reduce the Risk for Cancer Recurrence and/or Improves Survival?
The aging population has an increased prevalence of cancers in the setting of a progressive state
of vulnerability (frailty). Homeostenosis is the narrowing of the homeostatic functional capacity of
an organism. Deconditioning is the decreased ability to adapt to normal conditions, which can also
occur in patients with cancer. Therefore, under these conditions, morbidity and mortality after cancer
surgery is progressively increased and impaired because of the cancer itself. The individual’s level of
physical fitness prior to an operation may be predictive of postoperative outcome: physical fitness is an
overall term encompassing aerobic capacity, endurance, muscular strength and body composition [86].
Physical activity is known to reduce the risk for cancer development. Moreover, physical
activity performed both before surgery (prehabilitation), or after cancer surgery (rehabilitation),
improves immune function and metabolism, reduces length of stay, disability, complications, early
retirement, all-cause mortality, and even recurrence and mortality from some cancer types [95–97].
In the above-mentioned meta-analysis by Moran et al., the authors showed that inspiratory muscle
training, aerobic exercise, and resistance training, appears to decrease the incidence of all postoperative
complications, but does not influence postoperative LOS [93]. However, the number of available
studies was small and the methodological quality can be debated. For these reasons, prehabilitation
and rehabilitation (inspiratory muscle training, aerobic exercise, resistance training) remain promising
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strategies that deserve to be better studied in randomized trials and in association with other strategies
for reducing recurrence and increasing survival after cancer surgery, probably focusing on the right
patients subgroups, that need to be identified.
6. Conclusions
In conclusion, the hypothesis that anesthesia, analgesia and other perioperative interventions
such as optimizing nutrition and prehabilitation might influence cancer biology and therefore patient
outcomes is supported by some preclinical and clinical studies. The conflicting results highlight the
need to establish a large consortium, using innovative approaches, while linking data from multiple
sources and multiple techniques, and to undertake prospective, randomized, multicenter clinical trials.
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